Utah Medical Products Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, reporting third-quarter net income of $2,787 thousand and nine-month net income of $8,077 thousand.

Key Highlights

  • Q3 Net Sales: Net sales for the three months ended September 30, 2026 were $8,621 thousand, compared with $9,812 thousand in the same period of 2025, according to the filing.
  • Q3 Net Income: Net income for the quarter was $2,787 thousand, or $0.88 per basic and diluted share, versus $2,631 thousand, or $0.82 per share, in Q3 2025.
  • Nine-Month Performance: For the nine months ended September 30, 2026, net sales were $25,873 thousand and net income was $8,077 thousand, compared with $29,475 thousand and $8,720 thousand in the prior-year period.
  • Cash and Investments: Cash and investments stood at $85,202 thousand as of September 30, 2026, down from $85,756 thousand at December 31, 2025.
  • Acquisition Activity: The company reported net cash paid in acquisition of $4,042 thousand during the nine months ended September 30, 2026, with no comparable amount in the prior-year period.
  • Share Repurchases: The company purchased and retired 13 thousand shares during the nine-month period, at a total cost of $905 thousand, and paid dividends of $2,958 thousand to stockholders.
  • Shares Outstanding: Common shares outstanding as of November 12, 2026 were 2,849,541, the filing disclosed.

Utah Medical Products Results for the Nine Months and Quarter Ended September 30, 2026

According to the Form 10-Q filed on NASDAQ:UTMD, net sales for the three months ended September 30, 2026 totaled $8,621 thousand, a decrease from $9,812 thousand in the third quarter of 2025. Gross profit for the quarter was $4,840 thousand, compared with $5,604 thousand a year earlier. Operating income for Q3 2026 was $2,795 thousand, up from $2,611 thousand in Q3 2025, as total operating expenses declined to $2,045 thousand from $2,993 thousand. Other income contributed $606 thousand in Q3 2026 versus $698 thousand in Q3 2025.

For the nine months ended September 30, 2026, the filing reported net sales of $25,873 thousand against $29,475 thousand in the comparable 2025 period. Nine-month operating income was $8,009 thousand, versus $8,961 thousand a year prior. Net cash provided by operating activities for the nine-month period was $7,992 thousand, compared with $11,215 thousand in 2025. The company also reported capital expenditures of $500 thousand for property and equipment during the nine months, and net cash paid in acquisition of $4,042 thousand, which together drove net cash used in investing activities to $4,542 thousand.

As of September 30, 2026, total assets were $128,501 thousand, up from $122,542 thousand at December 31, 2025, the filing stated. Total stockholders' equity was $123,278 thousand, with retained earnings of $133,264 thousand. The accumulated other comprehensive loss widened to $(10,018) thousand from $(9,416) thousand at year-end 2025, reflecting foreign currency translation adjustments. The company disclosed stock-based compensation expense of $269 thousand for the nine-month period, and proceeds of $129 thousand from the issuance of common stock upon exercise of employee stock options.

What Was Disclosed

Utah Medical Products Inc. disclosed its unaudited consolidated financial results for the three and nine months ended September 30, 2026, including income statements, balance sheets, cash flow statements, and stockholders' equity statements, along with related notes and management's discussion.